Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Multiple Oral Doses of Apimostinel in Healthy Volunteers
NCT02366364Phase 1Completed
- Sponsor
- Allergan
- Start
- Feb 2015
- Primary completion
- Apr 2015
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of apimostinel in major depressive disorder (MDD) (4 arms), sponsored by Allergan. Primary endpoint: Number of participants with adverse events at 28 days. Started Feb 2015; status: completed.
02
Drugs
apimostinel
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02366364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02366364.